Tate & Lyle reaches botanical sweetener development milestone

Tate & Lyle and BioHarvest Sciences have produced a targeted botanical sweetening solution using BioHarvest’s plant cell cultivation platform, marking a new technical milestone in their ingredient development collaboration. The companies confirmed the result on 8 October 2026, following an expanded programme announced in May. Production of the intended composition has been demonstrated, but the partners have not disclosed its chemical identity, yields, regulatory authorisation, application performance or commercial availability. Those distinctions are central to interpreting the new result accurately.

The latest production milestone follows a collaboration established in December 2024 and expanded in May 2026 to investigate multiple plant-derived sweetener molecules. Tate & Lyle brings experience of sweetening systems and the behaviour of ingredients in food formulations, while BioHarvest is developing controlled production of botanical compositions through cultivated plant cells. Their objective is to investigate additional routes to ingredients that could contribute sweetness without relying solely on conventional agricultural harvesting and extraction. The October achievement establishes production of a targeted solution, not yet a commercial manufacturing operation for that ingredient.

Within that collaboration, BioHarvest’s Botanical Synthesis technology cultivates plant cells in controlled conditions so they generate compositions associated with the source plant. Instead of growing a mature crop and recovering the desired material after harvest, the process aims to obtain the target compounds from cultivated biological material. The approach can create a different set of controls for nutrient availability, process conditions and batch consistency. Its suitability for a particular ingredient depends on how reliably the cells produce that composition and how the material can be recovered and processed.

Although the target has been produced in development, commercial manufacture will require the partners to characterise the molecules, define their concentrations and demonstrate repeatability between batches. The identity of relevant molecules must be characterised and the concentrations of principal constituents established. Producers also need to examine other components that remain in the output, as well as variation between batches. Recovery, purification and standardisation can affect the final ingredient specification. The partners have not provided detailed analytical data from the latest milestone, so it is not possible to compare the material’s purity or concentration with commercial sweeteners already available.

Once an ingredient’s composition is known, its performance must be established in different food systems, since beverage, dairy and bakery formulations impose different requirements on sweetness and texture. In beverages, acidity, clarity, flavour and the onset and persistence of sweetness can affect a formulation’s acceptability. In bakery or confectionery products, sugar also contributes mass, texture, moisture behaviour and processing characteristics. Replacing sweetness alone may therefore leave functional gaps that require additional ingredients or process changes. Tate & Lyle’s formulation work is relevant to those constraints, but no finished-product application trial has been published for the latest botanical material.

Moving the cultivated cells beyond small development batches will also require control of their growth conditions, nutrient delivery and recovery of the desired composition. Cultivation conditions have to remain suitable for the cells while producing enough of the target compounds to meet the required specification. Mixing, nutrient distribution, oxygen supply and other operating variables can change with scale. Recovery operations and quality control must then convert the output into material that can be supplied consistently. BioHarvest has existing capabilities for botanical compositions, but those facilities do not establish commercial-scale validation of this particular sweetening solution.

Controlled cultivation may reduce exposure to some agricultural variations, but its energy requirements, material inputs and production economics still need to be assessed against crop-derived alternatives. Neither company has released a comparative lifecycle assessment, cost model or yield for the target sweetener. It would therefore be premature to claim a demonstrated environmental benefit, lower ingredient price or greater supply security. Such conclusions would depend on the eventual production process, plant utilisation, raw material requirements and recovery efficiency.

Even if the process becomes repeatable, commercial food use will depend on the ingredient’s identity, manufacturing method and regulatory status in each target market. The applicable rules depend on the identity of the ingredient, the process used to make it, the target jurisdiction and proposed conditions of consumption. A novel ingredient may require safety evaluation and market authorisation before use. No approval or regulatory submission for the newly produced solution has been disclosed, and no claim should be made that manufacturers can already purchase it for unrestricted commercial formulations.

Tate & Lyle could eventually incorporate a successful material into its existing sugar reduction and texture portfolio, provided the resulting ingredient meets each application’s specifications. The new collaboration may eventually broaden that range, but different food categories will require individual assessments of sensory quality, process tolerance and the function previously provided by sugar. The demonstrated production milestone will now need to be followed by repeatability trials, compositional characterisation, application testing and economic assessment before a commercial launch can be considered. No timetable for those steps has been announced.